Postchemotherapy immune status in infants with acute lymphoblastic leukemia: A report from the JPLSG MLL‐10 trial

The MLL‐10 trial (UMIN000004801) modified a Children's Oncology Group (COG) AALL0631 therapy for infants with KMT2A‐rearranged acute lymphoblastic leukemia (ALL). In 2016, one registered case developed secondary immunodeficiency during maintenance therapy and eventually died due to cytomegalovi...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2022-10, Vol.69 (10), p.e29772-n/a
Main Authors: Arakawa, Yuki, Hasegawa, Daisuke, Miyamura, Takako, Ohshima, Junjiro, Kimura, Shunsuke, Imamura, Toshihiko, Koga, Yuhki, Yamamoto, Shohei, Ogawa, Atsushi, Shinoda, Kunihiro, Eguchi, Mariko, Hosoi, Hajime, Imai, Kohsuke, Koh, Katsuyoshi, Tomizawa, Daisuke
Format: Article
Language:English
Subjects:
Acute lymphoblastic leukemia
Chemotherapy
Cytomegalovirus
Data collection
Hematology
Hematopoietic stem cells
Immune response
Immune status
Immune system
Immunodeficiency
infant
Infants
Leukemia
Oncology
Pediatrics
Remission
Stem cell transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The MLL‐10 trial (UMIN000004801) modified a Children's Oncology Group (COG) AALL0631 therapy for infants with KMT2A‐rearranged acute lymphoblastic leukemia (ALL). In 2016, one registered case developed secondary immunodeficiency during maintenance therapy and eventually died due to cytomegalovirus infection. Around the same time, fatal secondary immunodeficiencies were reported in five infants with ALL in North America who had received COG‐based chemotherapy between 1996 and 2015. Given these cases, we decided to conduct a retrospective study on the postchemotherapy immune status of infants with ALL. A questionnaire collected data on posttreatment immune function, frequency of infections, and supportive care for the 34 infants in the MLL‐10 trial. Patients receiving allogeneic hematopoietic stem cell transplantation in first remission were excluded. Responses to the survey were obtained in 28 cases (85%). Most patients were immunocompetent after the completion of chemotherapy (median follow‐up duration from the day of chemotherapy completion was 431 days), except for the aforementioned case. There were seven patients with nonsevere viral infection, all of whom recovered. In conclusion, severe chemotherapy‐induced immunodeficiency in infants with ALL appears to be rare, but prospective data collection of immune function is necessary to clarify this finding.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.29772